The in vitro susceptibility of several nonhuman primate species to human herpesvirus 6 (HHV-6) was investigated. Only peripheral blood mononuclear cells from chimpanzees (Pan troglodytes) were found permissive to productive infection by HHV-6, indicating that the host range of HHV-6, albeit limited, may not be restricted to Homo sapiens. However, natural HHV-6 infection in chimpanzees, as well as in the other species tested, could not be documented by serological analysis. As previously observed with human cells, HHV-6 infection of chimpanzee peripheral blood mononuclear cells was highly cytopathic and the infected cells exhibited phenotypic features of activated T lymphocytes. Although in humans the majority of HHV-6-infected lymphocytes displayed the CD4 antigen, in chimpanzees a mixed CD4+ and CD8+ phenotype was observed. HHV-6 was also shown to productively coinfect individual chimpanzee T cells with human immunodeficiency virus type 1, resulting in an accelerated induction of cytopathicity. In light of these findings, we propose the utilization of chimpanzees as a potential animal model system to investigate the in vivo interaction between HHV-6 and human immunodeficiency virus type 1 and its relevance to the development of acquired immune deficiency syndrome.
Although it is well established that human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired immune deficiency syndrome (AIDS) and related disorders (15) , other viral agents frequently detected in patients with AIDS and capable of transactivating the expression of HIV-1 may contribute to the disease progression (8, 21, 24, 25, 31, 32) . For example, human T-cell lymphotropic virus I (HTLV-I) was shown to coinfect the same target cells with HIV-1 (9) and to transactivate the long terminal repeat of HIV-1 (32) . In addition, seroepidemiological evidence seems to indicate that the disease progression to AIDS is accelerated in HIV-1-HTLV-I-coinfected individuals (4) . Another suitable candidate recently proposed as a potential cofactor in AIDS is human herpesvirus 6 (HHV-6) (21), a newly discovered herpesvirus originally identified by our group in patients with hematological disorders (19, 29) . HHV-6, which is predominantly a CD4+ T-lymphotropic virus (23, 33) , is also capable of transactivating the HIV-1 long terminal repeat (21) and productively coinfecting individual human T cells with HIV-1, causing an accelerated cytopathicity (21) . Moreover, a great proportion of the HHV-6 isolates obtained to date came from immunodeficient individuals (11, 20, 29, 34) and it was demonstrated by polymerase chain reaction analysis that the vast majority of AIDS patients (86%) harbor specific HHV-6 genetic material in their peripheral blood mononuclear cells (PBMCs) (7) .
A major hindrance to the interpretation of seroepidemiological analyses aimed at defining the relevance of in AIDS (for example, see references 1, 6, and 12) comes from the high prevalence of antibodies to this virus in the general population (ranging from around 60% to over 90%, according * Corresponding author.
to the different assays employed) (5, 30) . In addition, serological data by themselves could be inadequate to document the actual magnitude of viral expression in immunosuppressed individuals, particularly if HHV-6 directly contributes, by affecting CD4+ T lymphocytes, to the impairment of specific immune responses, including helper T-cell-driven antibody production by B lymphocytes.
The identification of suitable animal models may represent a valuable experimental tool to investigate the in vivo effects of potential human pathogens. For example, nonhuman primate models have been successfully used to study the pathogenicity of other human herpesviruses, such as Epstein-Barr virus (HHV-4) (13) . Experimental in vivo inoculation of HHV-6 may help to elucidate not only its acute and long-term pathogenic effects but also, in animals susceptible to both HHV-6 and HIV-1, its potential contribution to the pathogenesis of AIDS. Nonhuman primates and other species have been widely studied as possible animal models for AIDS. For example, HIV-1 has been successfully transmitted to chimpanzees (Pan troglodytes) (2) and gibbon apes (Hylobates lar) (22) . However, no significant clinical manifestations in infected animals were observed to date. In addition, a related human retrovirus, HIV-2, has been shown to persistently infect rhesus macaques (Macaca mulatta) (10) , a species which also provides the clinical model of immunodeficiency syndrome most reminiscent of human AIDS, i.e., simian AIDS, when infected by retroviruses of the simian immune virus group (14) .
In an attempt to identify possible animal models for M01-CO-74102 with the National Cancer Institute. All other specimens were obtained from animals housed in facilities at Bionetics Research Inc., Rockville, Md. Two of the gibbon apes used in these studies had been previously exposed to HTLV-I and had developed a specific serological response. Four gibbon apes, five chimpanzees, five rhesus macaques, and four African green monkeys had been previously inoculated with HIV-1 (strain HTLV-IIIB), resulting in persistent infection in both the gibbon apes and the chimpanzees. Six additional rhesus macaques and three African green monkeys had been inoculated with HIV-2 (different strains) and presented variable degrees of antibody response to the virus. PBMCs from healthy adult human volunteers (>500) have also been studied in the course of over 2 years for in vitro susceptibility to HHV-6, and some of them were included in this study as controls of the infection efficiency in phytohemagglutininstimulated PBMCs.
Infection with HHV-6 or HIV-1 in vitro. PBMCs (10 x 106) from the various animals were activated in vitro by cultivation for 36 h at 37°C in a humidified 5% CO2 atmosphere in culture medium (RPMI 1640) supplemented with 10% fetal bovine serum and 2.5 ,ug of purified phytohemagglutinin per ml. Cells were then washed, pelleted, and suspended in 1 ml of stock HHV-6, at an approximate multiplicity of infection of 1. For dual infection experiments, both HHV-6 and HIV-1 were added simultaneously, each virus at a multiplicity of infection of approximately 1. After 1 h at 37°C, the cells were washed and suspended at a density of 106/ml in culture medium supplemented with 10% fetal bovine serum and 10% delectinated native interleukin-2 (Advanced Biotechnologies, Inc., Columbia, Md. receptor (CD71) expression on the surface membranes of HHV-6-infected chimpanzee cells may be surprising, since it was previously documented on the human counterpart (23), but could be explained by nonconservation of the epitope recognized by the OKT9 MAb. In fact, the MAb ligand was also undetectable on positive-control autologous cells (i.e., uninfected phytohemagglutinin-activated chimpanzee PBMCs).
Dual infection of chimpanzee T lymphocytes with HHV-6 and HIV-1. Dual infection experiments were performed by simultaneously exposing chimpanzee PBMCs to both HHV-6 and HIV-1, each virus at a multiplicity of infection of approximately 1. By day 6 postinfection, two-color indirect IF demonstrated that specific antigens of both HHV-6 and HIV-1 were simultaneously expressed in individual cells (Fig. 2) . These HHV-6-and HIV-1-positive cells consistently exhibited a T-lymphocytic phenotype. In addition, as previously observed with human PBMCs (21), an accelerated cytopathic effect was observed in dually infected cultures, compared with those infected with either virus alone (data not shown).
Since some of the animals used in this study had been previously inoculated with HIV-1 (strain HTLV-IIIB), expression of this retrovirus was also monitored in cell cultures not exposed to HIV-1 in vitro. However, the culture conditions employed in this study were not optimal for HIV-1 expression, commonly requiring coculture of test cells with uninfected allogenic leukocytes. Indeed, cultures from only one of the five HIV-1-infected chimpanzees yielded endogenous HIV-1 activity. Such activity was identified by using different assays (i.e., reverse transcriptase enzymatic activity, p24 gag antigen capture, and electron microscopy) in both primary and HHV-6-infected PBMC cultures. In these latter cultures, electron microscopy ( chimpanzee T lymphocytes were productively coinfected by HHV-6 and HIV-1 (Fig. 3) .
Serological analysis of HHV-6 prevalence in nonhuman primates. Serum specimens from several nonhuman primates kept in captivity, including 22 adult chimpanzees, were studied for the presence of antibodies toward HHV-6 by indirect IF analysis on acetone-fixed infected human lymphoid cells (Table 1) . Three standard serum dilutions were employed in the first screening (i.e., 1:5, 1:10, and 1:20). The vast majority of the serum specimens were negative at all three dilutions tested. Despite a very weak signal detectable at the 1:5 dilution in serum specimens from 2 of 22 chimpanzees and 1 of 12 rhesus macaques, none of the animals was considered antibody positive to HHV-6 antigens.
DISCUSSION
Following our original isolation of HHV-6 (initially referred to as human B-lymphotropic virus) (29) , several attempts have been made to elucidate its role in human pathology. For example, HHV-6-specific genetic material has been identified in neoplastic tissues from occasional B-cell and T-cell lymphomas (17, 18 ) and a possible association with some forms of persistent lymphadenopathy has been proposed (28) , but the significance of these findings remains uncertain. More conclusively, primary infection by HHV-6 has been recently linked to the etiology of a common febrile disease of infancy, exanthem subitum (36) . It may perhaps be significant that despite the high seroprevalence in the general population (6, 30) , HHV-6 isolates have been obtained most frequently from immunosuppressed individuals, including patients with AIDS (11, 20, 29, 34) . These patients exhibit a profound and selective depletion of CD4+ T lymphocytes (15) , a subset of T cells playing a crucial role in the generation of both humoral and cellular immune responses. Since HHV-6 was shown to exert a dramatic cytopathic effect on CD4+ T cells (23) , it would be particularly intriguing to elucidate the relevance of this virus to the progression of HIV-1 infection toward AIDS.
The experiments described here were prompted by the need for the identification of suitable animal model systems for HHV-6 infection and, possibly, for the investigation of the combined infection by HHV-6 and HIV-1. In the perspective of future in vivo studies, we have screened the in vitro susceptibility to HHV-6 of PBMCs from a number of nonhuman primate species, including chimpanzees, gibbon apes, rhesus macaques, African green monkeys, tamarins, and marmosets. The cells from all these animals, except the chimpanzee, were found refractory to HHV-6 infection. This observation suggests that HHV-6, similar to human cytomegalovirus (human herpesvirus 5), has a remarkable degree of species specificity. The efficiency of HHV-6 infection, the yield of infectious virus, and its target cell characteristics in chimpanzee PBMCs were remarkably similar to previous observations in humans, suggesting that these species may represent a suitable animal model for the study of HHV-6 infectivity and pathogenicity. For both chimpanzees and humans, HHV-6 is predominantly infectious and cytopathic for cells of the T-lymphocytic lineage, exhibiting a number of T-cell activation markers. The major phenotypic discrepancy between chimpanzee and human HHV-6-infected cells was the lower CD4/CD8 ratio, averaging approximately 1 (for humans, most HHV-6-infected cells were CD4+) (23).
However, this observation is consistent with the lower CD4/CD8 ratios normally observed in the peripheral blood of uninfected chimpanzees (averaging approximately 1) (16) .
Serologic analysis of a limited number of animals failed to document the presence of specific anti-HHV-6 antibodies in any of the Old World and New World nonhuman primates tested. In particular, serum specimens from 22 chimpanzees were negative, indicating that natural exposure to HHV-6 in these animals, if present, is not a frequent phenomenon. These data are consistent with those of our previous report (29) , in which serum specimens from diverse nonhuman primates, including five chimpanzees, had negative results for antibodies to HHV-6. Since chimpanzees are apparently naive to HHV-6, we believe that the experimental inoculation in vivo could also provide precious clinical and immunological information on the host response to primary infection.
One finding that may have important implications is the observation that individual chimpanzee T lymphocytes can be productively coinfected by HHV-6 and HIV-1, resulting in an accelerated cytopathic effect. Therefore, the chimpanzee may also represent a suitable animal model for the study of the in vivo interaction between HHV-6 and HIV-1 and its role in the development of immunodeficiency. It is well established that chimpanzees can be chronically infected with HIV-1 and develop permanent humoral and cellular immune responses toward the virus (14, 27) . However, besides the transient appearance of variable degrees of lymphadenopathy and minor hematological abnormalities (14, 27) , no major signs of disease have been observed to date in any of the HIV-1-infected animals. This lack of clinical evolution could be related to certain specific biological characteristics of chimpanzees, such as a natural resistance, possibly due to nonpermissiveness of chimpanzee macrophages to HIV-1 infection (26). However, another important factor to be considered is the protected environment where the animals are kept, which prevents repeated contacts with common pathogens or opportunisitic agents. In particular, exposure to one (or more than one) cofactor(s) could be critical for the development of clinical manifestations, ultimately leading to full-blown AIDS. In this respect, HHV-6 represents a particularly interesting candidate. We have shown here that chimpanzee T lymphocytes are highly permissive to HHV-6 infection, as well as to productive coinfection by and HIV-1. On the basis of these findings, we believe that the utilization of chimpanzees as an in vivo model of dual HIV-1-HHV-6 infection would be a rational approach to define the potential role of HHV-6 as a cofactor in AIDS.
